Neurocrine Biosciences (NBIX) EBT Margin Growth (5y) (2016 - 2026)
Neurocrine Biosciences (NBIX) EBT Margin Growth (5y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - |
| 10 | Alkermes | 8.02 Bn | 7.37 Bn | 397.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -299.00 |
| Mar 31, 2026 | 1,880.00 |
| Dec 31, 2025 | 1,290.00 |
| Sep 30, 2025 | 5,880.00 |
| Jun 30, 2025 | -431.00 |
| Mar 31, 2025 | -1,384.00 |
| Dec 31, 2024 | 1,009.00 |
| Sep 30, 2024 | 430.00 |
| Jun 30, 2024 | -1,169.00 |
| Mar 31, 2024 | 8,083.00 |
| Dec 31, 2023 | 2,420.00 |
| Sep 30, 2023 | -1,028.00 |
| Jun 30, 2023 | 3,296.00 |
| Mar 31, 2023 | 3,426.00 |
| Dec 31, 2022 | 1,772.00 |
| Sep 30, 2022 | 5,122.00 |
| Jun 30, 2022 | 95,756.00 |
| Mar 31, 2021 | 14,563.00 |
| Mar 31, 2020 | 2,668.00 |
| Dec 31, 2018 | 204,455.00 |